Why combination products will reshape regulated markets
The regulated pathways of the next decade reward teams that treat device, drug and data as a single therapeutic system — not three separate submissions.
Read — coming soonInsights
A slowly growing library of letters, essays and observations from AnilSka — on medicine, systems, capital and the long horizons that make institutions worth building.
The regulated pathways of the next decade reward teams that treat device, drug and data as a single therapeutic system — not three separate submissions.
Read — coming soonA note on why we default to stewardship rather than exit, what it costs to mean it, and how holding periods change what an owner is willing to build.
Read — coming soonHow the shape of a system quietly determines what its operators are permitted to do — and why governance work belongs, in part, inside the architecture itself.
Read — coming soonA first letter from the founders of AnilSka on the meaning of the name, the horizons we work on, and what our founders can expect from us in return.
Read — coming soonCorridors of trust between Australia, Canada and Sri Lanka behave less like transactions and more like slowly appreciating infrastructure.
Read — coming soonIn regulated healthcare the winning move is often the deferred one — restraint about where AI is inserted, and where practitioner judgement is protected.
Read — coming soon